Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ: ALNY )

266.54 +1.55 (+0.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran. 
Via Benzinga
Exposures Product Safety
Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer
Its heart disease drug could gain approval, but FDA advisors don't expect it to take on Pfizer's leading drug. 
Via Investor's Business Daily
Exposures Product Safety
Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran. 
Via Benzinga
Exposures Product Safety
What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
Nasdaq, S&P 500 Futures In Green As Traders Look Past Inflation Data; Analyst Singles Out Key Catalyst That Can Keep Year's Rally Going
US stocks could open Thursday's session higher, apparently in relief rally following the August inflation data. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments. 
Via InvestorPlace
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Analyst Expectations for Alnylam Pharmaceuticals's Future
Via Benzinga
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time, 
Via Benzinga
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,  
Via Benzinga
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
3 Stocks to Buy For the COVID Resurgence
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting 
Via MarketBeat
Exposures COVID-19 Product Safety
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals
Via Business Wire
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook
Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key  
Via Benzinga
Lululemon Athletica To Rally Around 12%? Here Are 10 Other Analyst Forecasts For Tuesday
Needham raised the price target for F5, Inc. (NASDAQ: FFIV) from $175 to $180. Needham analyst Alex Henderson maintained a Buy rating. F5 shares jumped 11.2% to $167.00 in pre-market trading. 
Via Benzinga
Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories
Wall Street Journal 
Via Benzinga
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to  
Via Benzinga
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Why Shares of BridgeBio Pharma Skyrocketed This Week
The biotech company saw strong results in a phase 3 trial. 
Via The Motley Fool
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.